Combined oral contraceptives for the treatment of acne: A practical guide

Cutis

Volumn 90, Issue 2, 2012, Pages 83-90

  Arrington, Elizabeth A ^a   Patel, Nishit S ^a   Gerancher, Karen ^b   Feldman, Steven R ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ACNE VULGARIS; ARTICLE; COUNSELING; FEMALE; HUMAN; PRACTICE GUIDELINE; RISK ASSESSMENT;

ACNE VULGARIS; CONTRACEPTIVES, ORAL, COMBINED; COUNSELING; ESTROGENS; FEMALE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROGESTINS; RISK ASSESSMENT;

EID: 84871856945     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Layton AM. A review on the treatment of acne vulgaris. Int J Clin Pract. 2006;60:64-72.
2. Tan J. Hormonal treatment of acne: review of current best evidence. J Cutan Med Surg. 2004;(8, suppl 4):S11-S15.
3. Helms SE, Bredle DL, Zajic J, et al. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol. 1997;36(5, pt 1):705-710.
4. ACOG Committee on Practice Bulletin-Gynecology. ACOG practice bulletin. no. 73: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107:1453-1472.
5. Katsambas A, Papakonstantinou A. Acne: systemic treatment. Clin Dermatol. 2004;22:412-418.
6. Essah PA, Wickham EP 3rd, Nunley JR, et al. Dermatology of androgen-related disorders. Clin Dermatol. 2006;24:289-298.
7. Johnson BA, Nunley JR. Use of systemic agents in the treatment of acne vulgaris [published correction in Am Fam Physician. 2001;63:following 1295]. Am Fam Physician. 2000;62:1823-1830.
8. Golden NH, Carlson JL. The pathophysiology of amenorrhea in the adolescent. Ann N Y Acad Sci. 2008;1135:163-178.
9. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol. 2004;190(suppl 4):S5-S22.
10. Lucky AW, Henderson TA, Olson WH, et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol. 1997;37(5, pt 1):746-754.
11. Redmond GP, Olson WH, Lippman JS, et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol. 1997;89:615-622.
12. Estrostep Fe [package insert]. Rockaway, NJ: Warner Chilcott US; 2009.
13. Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease [published correction in J Am Coll Cardiol. 2009;53:904]. J Am Coll Cardiol. 2009;53:221-231.
14. Goodman G. Managing acne vulgaris effectively. Aust Fam Physician. 2006;35:705-709.
15. Haroun M. Hormonal therapy of acne. J Cutan Med Surg. 2004;(8, suppl 4):S6-S10.
16. Rimsza ME. Counseling the adolescent about contraception. Pediatr Rev. 2003;24:162-170.
17. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management [published online ahead of print February 5, 2007]. J Am Acad Dermatol. 2007;56:651-663.
18. Arowojolu AO, Gallo MF, Lopez LM, et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2007;1:CD004425.
19. Petitti DB. Clinical practice. combination estrogen-progestin oral contraceptives [published correction in N Engl J Med. 2004;350:92]. N Engl J Med. 2003;349:1443-1450.
20. Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004;22:419-428.
21. Harper JC. Should dermatologists prescribe hormonal contraceptives for acne? Dermatol Ther. 2009;22:452-457.
22. Spencer AL, Bonnema R, McNamara MC. Helping women choose appropriate hormonal contraception: update on risks, benefits, and indications. Am J Med. 2009;122:497-506.
23. World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 3rd ed. Geneva, Switzerland: World HealthOrganization; 2004. http://whqlibdoc.who.int/publications/2004/9241562668.pdf. Accessed July 25, 2012.
24. Practice Committee of the American Society for Reproductive Medicine. Hormonal contraception: recent advances and controversies. Fertil Steril. 2006;86(5, suppl 1):S229-S235.
25. Deligeoroglou E, Christopoulos P, Creatsas G. Contraception in adolescence. Ann N Y Acad Sci. 2006;1092:78-90.
26. Lawrenson R, Farmer R. Venous thromboembolism and combined oral contraceptives: does the type of progestogen make a difference? Contraception. 2000;62(suppl 2):21S-28S.
27. Suissa S, Blais L, Spitzer WO, et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception. 1997;56:141-146.
28. Tan JK, Ediriweera C. Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne. Int J Womens Health. 2010;1:213-221.
29. Martinez F, Avecilla A. Combined hormonal contraception and venous thromboembolism. Eur J Contracept Reprod Health Care. 2007;12:97-106.
30. Carr BR, Ory H. Estrogen and progestin components of oral contraceptives: relationship to vascular disease. Contraception. 1997;55:267-272.
31. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1996;347:1713-1727.
32. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346:2025-2032.
33. Faculty of Family Planning and Reproductive Health Care, Clinical Effectiveness Unit. FFPRHC Guidance (October 2003): first prescription of combined oral contraception. J Fam Plann Reprod Health Care. 2003;29:209-222.
34. Appleby P, Beral V, Berrington de González A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370:1609-1621.
35. Harris TG, Miller L, Kulasingam SL, et al. Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection. Am J Obstet Gynecol. 2009;200:489, e1-e8.
36. Lee J, Jezewski MA. Attitudes toward oral contraceptive use among women of reproductive age: a systematic review. ANS Adv Nurs Sci. 2007;30:e85-e103.
37. Fernandez E, La Vecchia C, Balducci A, et al. Oral contraceptives and colorectal cancer risk: a meta-analysis. Br J Cancer. 2001;84:722-727.
38. Lesnewski R, Prine L. Initiating hormonal contraception. Am Fam Physician. 2006;74:105-112.
39. Segebladh B, Borgström A, Odlind V, et al. Prevalence of psychiatric disorders and premenstrual dysphoric symptoms in patients with experience of adverse mood during treatment with combined oral contraceptives [published online ahead of print September 11, 2008]. Contraception. 2009;79:50-55.
40. Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg. 2008;27:197-206.
41. Gardner J, Miller L. Promoting the safety and use of hormonal contraceptives. J Womens Health (Larchmt). 2005;14:53-60.
42. Meckstroth KR. Physical examination before initiating hormonal contraception: what is necessary? Am Fam Physician. 2006;74:32, 34.
43. Scott A, Glasier AF. Are routine breast and pelvic examinations necessary for women starting combined oral contraception [published online ahead of print June 10, 2004]? Hum Reprod Update. 2004;10:449-452.
44. Stewart FH, Harper CC, Ellertson CE, et al. Clinical breast and pelvic examination requirements for hormonal contraception: current practice vs evidence. JAMA. 2001;285:2232-2239.
45. ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin no. 109: cervical cytology screening. Obstet Gynecol. 2009;114:1409-1420.
46. Westhoff C, Heartwell S, Edwards S, et al. Initiation of oral contraceptives using a quick start compared with a conventional start: a randomized controlled trial. Obstet Gynecol. 2007;109:1270-1276.
47. World Health Organization. Selected Practice Recommendations for Contraceptive Use. 2nd ed. Geneva, Switzerland: World Health Organization; 2005.
48. Rosenberg MJ, Burnhill MS, Waugh MS, et al. Compliance and oral contraceptives: a review. Contraception. 1995;52:137-141.
49. Cheung E, Free C. Factors influencing young women's decision making regarding hormonal contraceptives: a qualitative study. Contraception. 2005;71:426-431.